Back to Authors

Tao, Randa

https://orcid.org/0000-0001-9379-4732

Mayo Clinic

Mayo Clinic

Citations 13

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Hoppe, Richard T. , Advani, Ranjana H. , Ambinder, Richard F. , Armand, Philippe , Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Dabaja, Bouthaina S. , Daly, Megan E. , Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Johnston, Patrick B. , Kaminski, Mark , Kenkre, Vaishalee P. , Lynch, Ryan C. , Maddocks, Kami J. , Metzger, Monika L. , Morgan, David , Mulroney, Carolyn , Pullarkat, Sheeja T. , Rabinovitch, Rachel , Rosenspire, Karen C., Seropian, Stuart , Tao, Randa , Torka, Pallawi , Yang, Joanna C. , Burns, Jennifer L. , Campbell, Mallory, Sundar, Hema, Advani, Ranjana H , Hoppe, Richard T , Ambinder, Richard F , Tao, Randa , Ai, Weiyun Z. , Gordon, Leo I. , Kelsey, Chris R. , Khan, Nadia , McConathy, Jonathan , Winter, Jane N. , Yahalom, Joachim

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 322-334

10.6004/jnccn.2022.0021 Get It

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Hoppe, Richard T. , Advani, Ranjana H. , Ambinder, Richard F. , Armand, Philippe , Bello, Celeste, Benitez, Cecil M. , Bierman, Philip J., Boughan, Kirsten M, Dabaja, Bouthaina S. , Hernandez‐Ilizaliturri, Francisco J. , Herrera, Alex F. , Hochberg, Ephraim P. , Johnston, Patrick B. , Kaminski, Mark , Kenkre, Vaishalee P. , Khan, Nadia , Lynch, Ryan C. , Maddocks, Kami J. , McKinney, Matthew , Metzger, Monika L. , Morgan, David , Mulroney, Carolyn , Rabinovitch, Rachel , Rosenspire, Karen C., Seropian, Stuart , Burns, Jennifer L. , Ogba, Ndiya , Advani, Ranjana H , Khan, Nadia , Hoppe, Richard T , Ambinder, Richard F , Ai, Weiyun Z. , Gordon, Leo I. , Huang, Jiayi , McConathy, Jonathan , Tao, Randa , Winter, Jane N. , Yahalom, Joachim

Journal of the National Comprehensive Cancer Network | June 5, 2020 | Volume: 18 | Issue: 6 | Pages: 755-781

10.6004/jnccn.2020.0026 Get It

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival
Baraghoshi, David , Garrido‐Laguna, Ignacio , Gilcrease, Glynn Weldon, Whisenant, Jonathan, Weis, John R., Scaife, Courtney L. , Pickron, T. Bartley, Huang, Lyen C. , Monroe, Marcus M. , Abdelaziz, Sarah, Fraser, Alison , Deshmukh, Vikrant , Rowe, Kerry , Snyder, John , Samadder, N. Jewel , Hashibe, Mia, Samadder, Niloy J, Lloyd, Shane , Tao, Randa , Smith, Ken R. , Newman, Michael , Snyder, John

American Journal of Clinical Oncology | March 18, 2019 | Volume: 42 | Issue: 4 | Pages: 355-362

10.1097/coc.0000000000000529 Get It

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort. The risk of developing a mental illness was compared between cohorts. The association between mental illness and mortality was also analyzed. Results: In total, 8961 CRC survivors and 35,897 individuals in a general population cohort were identified. CRC survivors were at increased risk for any mental health diagnosis at 0 to 2 years (hazard ratio [HR], 3.70; 95% confidence interval [CI], 3.47-3.95), >2 to 5 years (HR, 1.23; 95% CI, 1.09-1.38), and >5 years (HR, 1.20; 95% CI, 1.07-1.36) after cancer diagnosis. CRC survivors were also at increased risk of depressive disorders specifically during the same time periods. At >5 years, CRC survivors still had an increased risk of developing many mental health diagnoses. Factors associated with increased risk of any mental health disorder among CRC survivors included colostomy and Charlson Comorbidity Index of 1+. There was an increased risk of death for CRC survivors diagnosed with any mental health disorder (HR, 2.18; 95% CI, 2.02-2.35) and depression (HR, 2.10; 95% CI, 1.92-2.28). Conclusions: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival.